My NCBISign In
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Francisco J Esteva, Jing Wang, Feng Lin, Jaime A Mejia, Kai Yan, Kadri Altundag, Vicente Valero, Aman U Buzdar, Gabriel N Hortobagyi, W Fraser Symmans, Lajos Pusztai
Breast Cancer Res. 2007; 9(6): R87. Published online 2007 December 17. doi: 10.1186/bcr1836
PMCID:
PMC2246190
Abstract Full Text PDF–628K

Is Cited by the Following 2 Articles in this Archive:

Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
John Stagg, Sherene Loi, Upulie Divisekera, Shin Foong Ngiow, Helene Duret, Hideo Yagita, Michele W. Teng, Mark J. Smyth
Proc Natl Acad Sci U S A. 2011 April 26; 108(17): 7142–7147. Published online 2011 April 11. doi: 10.1073/pnas.1016569108
PMCID:
PMC3084100
Abstract Full Text PDF–252K Supplementary Material
Molecular targeted therapies for breast cancer treatment
Claus M Schlotter, Ulf Vogt, Heike Allgayer, Burkhard Brandt
Breast Cancer Res. 2008; 10(4): 211. Published online 2008 July 24. doi: 10.1186/bcr2112
PMCID:
PMC2575526
Abstract Full Text PDF–464K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk